U.S. Markets closed

Orexo AB (publ) (ORXOY)

Other OTC - Other OTC Delayed Price. Currency in USD
1.70990.0000 (0.00%)
At close: 10:30AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.7099
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.7099 - 1.7099
52 Week Range1.7099 - 2.8200
Avg. Volume1
Market Cap58.731M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Orexo postpones publication of the Annual Report

    Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023. The previously announced date for publication was March 24, 2023. The change in date is due to prolonged audit of the financial reporting in the European Single Electronic Format, ESEF.

  • PR Newswire

    Notice of Annual General Meeting of Orexo

    The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Tuesday 18 April 2023, at 16.00 pm in Orexo's facilities at Rapsgatan 7E in Uppsala, Sweden.

  • PR Newswire

    Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose

    Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its lead pharmaceutical pipeline asset, OX124, a nasal rescue medication for opioid overdose. OX124, is based on Orexo´s drug delivery platform amorphOX® and contains a high-dose of naloxone.